Monitoring of lung involvement in rheumatologic disease

Respiration

Volumn 91, Issue 2, 2016, Pages 89-98

  Paschalaki, Koralia E ^a,c   Jacob, Joseph ^b   Wells, Athol U ^c  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b Department of Radiology ^*  (United Kingdom)

^c ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

Chest radiography; Connective tissue disease; Monitoring; Pulmonary function tests; Pulmonary hypertension; Symptomatic change

Indexed keywords

ARTICLE; CLINICAL EVALUATION; CONNECTIVE TISSUE DISEASE; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; ECHOCARDIOGRAPHY; ECHOGRAPHY; EXERCISE TEST; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG ECHOGRAPHY; LUNG FUNCTION; LUNG FUNCTION TEST; MULTICENTER STUDY (TOPIC); OXYGEN DESATURATION; PATIENT MONITORING; PRIORITY JOURNAL; PULMONARY HYPERTENSION; THORAX RADIOGRAPHY; COMPLICATION; DIAGNOSTIC IMAGING; HEALTH SURVEY; LUNG; LUNG DISEASES; RHEUMATIC DISEASE;

HUMANS; LUNG; LUNG DISEASES; POPULATION SURVEILLANCE; RESPIRATORY FUNCTION TESTS; RHEUMATIC DISEASES;

EID: 84959148640     PISSN: 00257931     EISSN: 14230356     Source Type: Journal    
DOI: 10.1159/000442890     Document Type: Article

References (75)

1. Nihtyanova SI, Schreiber BE, Ong VH, Rosenberg D, Moinzadeh P, Coghlan JG, Wells AU, Denton CP: PreDiction of pulmonary complications and long-term survival in systemic sclerosis. Arthritis Rheumatol 2014; 66: 1625-1635.
2. Collard HR, King TE Jr, Bartelson BB, Vourlekis JS, Schwarz MI, Brown KK: Changes in clinical and physiologic variables preDict survival in iDiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003; 168: 538-542.
3. American Thoracic Society/European Respiratory Society International MultiDisciplinary Consensus Classification of the IDiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of Directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002; 165: 277-304.
4. Martinez FJ, Safrin S, Weycker D, Starko KM, Bradford WZ, King TE Jr, Flaherty KR, Schwartz DA, Noble PW, Raghu G, Brown KK: The clinical course of patients with iDiopathic pulmonary fibrosis. Ann Intern Med 2005; 142: 963-967.
5. Yorke J, Swigris J, Russell AM, Moosavi SH, Ng Man Kwong G, Longshaw M, Jones PW: Dyspnea-12 is a valid and reliable measure of breathlessness in patients with interstitial lung Disease. Chest 2011; 139: 159-164.
6. Manali ED, Lyberopoulos P, Triantafillidou C, Kolilekas LF, Sotiropoulou C, Milic-Emili J, Roussos C, Papiris SA: MRC chronic Dyspnea Scale: relationships with carDiopulmonary exercise testing and 6-minute walk test in iDiopathic pulmonary fibrosis patients: a prospective study. BMC Pulm Med 2010; 10: 32.
7. Nishiyama O, Taniguchi H, Kondoh Y, Kimura T, Kato K, Kataoka K, Ogawa T, Watanabe F, Arizono S: A simple assessment of dyspnoea as a prognostic inDicator in iDiopathic pulmonary fibrosis. Eur Respir J 2010; 36: 1067-1072.
8. Saketkoo LA, Mittoo S, Huscher D, Khanna D, Dellaripa PF, Distler O, Flaherty KR, Frankel S, OdDis CV, Denton CP, et al: Connective tissue Disease related interstitial lung Diseases and iDiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials. Thorax 2014; 69: 428-436.
9. Chung L, Liu J, Parsons L, Hassoun PM, Mc-Goon M, Badesch DB, Miller DP, Nicolls MR, Zamanian RT: Characterization of connective tissue Disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest 2010; 138: 1383-1394.
10. Condliffe R, Kiely DG, Peacock AJ, Corris PA, Gibbs JS, Vrapi F, Das C, Elliot CA, Johnson M, DeSoyza J, et al: Connective tissue Diseaseassociated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 2009; 179: 151-157.
11. Condliffe R, Howard LS: Connective tissue Disease-associated pulmonary arterial hypertension. F1000Prime Rep 2015; 7: 06.
12. Wang X, Lou M, Li Y, Ye W, Zhang Z, Jia X, Shi H, Zhu X, Wang L: CarDiovascular involvement in connective tissue Disease: the role of interstitial lung Disease. PLoS One 2015; 10:e0121976.
13. Saketkoo LA, Mittoo S, Frankel S, LeSage D, Sarver C, Phillips K, Strand V, Matteson EL: Reconciling healthcare professional and patient perspectives in the development of Disease activity and response criteria in connective tissue Disease-related interstitial lung Diseases. J Rheumatol 2014; 41: 792-798.
14. Khanna D, Mittoo S, Aggarwal R, Proudman SM, Dalbeth N, Matteson EL, Brown K, Flaherty K, Wells AU, Seibold JR, Strand V: Connective tissue Disease-associated interstitial lung Diseases (CTD-ILD)-report from OMERACT CTD-ILD Working Group. J Rheumatol 2015; 42: 2168-2171.
15. Keogh BA, Crystal RG: Clinical significance of pulmonary function tests. Pulmonary function testing in interstitial pulmonary Disease. What does it tell us? Chest 1980; 78: 856-865.
16. Latsi PI, du Bois RM, Nicholson AG, Colby TV, Bisirtzoglou D, Nikolakopoulou A, Veeraraghavan S, Hansell DM, Wells AU: Fibrotic iDiopathic interstitial pneumonia: the prognostic value of longituDinal functional trends. Am J Respir Crit Care Med 2003; 168: 531-537.
17. Flaherty KR, Mumford JA, Murray S, Kazerooni EA, Gross BH, Colby TV, Travis WD, Flint A, Toews GB, Lynch JP 3rd, Martinez FJ: Prognostic implications of physiologic and raDiographic changes in iDiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003; 168: 543-548.
18. Morgan C, Knight C, Lunt M, Black CM, Silman AJ: PreDictors of end stage lung Disease in a cohort of patients with scleroderma. Ann Rheum Dis 2003; 62: 146-150.
19. Steen VD, Conte C, Owens GR, Medsger TA Jr: Severe restrictive lung Disease in systemic sclerosis. Arthritis Rheum 1994; 37: 1283-1289.
20. Wells AU, Hansell DM, Rubens MB, King AD, Cramer D, Black CM, du Bois RM: Fibrosing alveolitis in systemic sclerosis: inDices of lung function in relation to extent of Disease on computed tomography. Arthritis Rheum 1997; 40: 1229-1236.
21. Hansell DM, Rubens MB, Padley SP, Wells AU: Obliterative bronchiolitis: inDividual CT signs of small airways Disease and functional correlation. RaDiology 1997; 203: 721-726.
22. Gould GA, Redpath AT, Ryan M, Warren PM, Best JJ, Flenley DC, MacNee W: Lung CT density correlates with measurements of airflow limitation and the Diffusing capacity. Eur Respir J 1991; 4: 141-146.
23. Wells AU, Desai SR, Rubens MB, Goh NS, Cramer D, Nicholson AG, Colby TV, du Bois RM, Hansell DM: IDiopathic pulmonary fibrosis: a composite physiologic index derived from Disease extent observed by computed tomography. Am J Respir Crit Care Med 2003; 167: 962-969.
24. Schurawitzki H, Stiglbauer R, Graninger W, Herold C, Pölzleitner D, Burghuber OC, Tscholakoff D: Interstitial lung Disease in progressive systemic sclerosis: high-resolution CT versus raDiography. RaDiology 1990; 176: 755-759.
25. Epler GR, McLoud TC, Gaensler EA, Mikus JP, Carrington CB: Normal chest roentgenograms in chronic Diffuse infiltrative lung Disease. N Engl J Med 1978; 298: 934-939.
26. Franquet T, Gimenez A, Monill JM, Diaz C, Geli C: Primary Sjögren's syndrome and associated lung Disease: CT finDings in 50 patients. AJR Am J Roentgenol 1997; 169: 655-658.
27. Dawson JK, Fewins HE, Desmond J, Lynch MP, Graham DR: Fibrosing alveolitis in patients with rheumatoid arthritis as assessed by high resolution computed tomography, chest raDiography, and pulmonary function tests. Thorax 2001; 56: 622-627.
28. Goh NS, Desai SR, Veeraraghavan S, Hansell DM, Copley SJ, Maher TM, Corte TJ, Sander CR, Ratoff J, Devaraj A, et al: Interstitial lung Disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008; 177: 1248-1254.
29. Lichtenstein DA: Ultrasound in the management of thoracic Disease. Crit Care Med 2007; 35:S250-S261.
30. Sperandeo M, Varriale A, Sperandeo G, Filabozzi P, Piattelli ML, Carnevale V, Decuzzi M, Vendemiale G: Transthoracic ultrasound in the evaluation of pulmonary fibrosis: our experience. Ultrasound Med Biol 2009; 35: 723-729.
31. Barskova T, Gargani L, Guiducci S, Randone SB, Bruni C, Carnesecchi G, Conforti ML, Porta F, Pignone A, Caramella D, et al: Lung ultrasound for the screening of interstitial lung Disease in very early systemic sclerosis. Ann Rheum Dis 2013; 72: 390-395.
32. Delle SeDie A, Carli L, Cioffi E, BombarDieri S, Riente L: The promising role of lung ultrasound in systemic sclerosis. Clin Rheumatol 2012; 31: 1537-1541.
33. Cogliati C, Antivalle M, Torzillo D, Birocchi S, Norsa A, Bianco R, Costantino G, Ditto MC, Battellino M, Sarzi Puttini PC, Montano N: Standard and pocket-size lung ultrasound devices can detect interstitial lung Disease in rheumatoid arthritis patients. Rheumatology (Oxford) 2014; 53: 1497-1503.
34. Bonella F, Costabel U: Biomarkers in connective tissue Disease-associated interstitial lung Disease. Semin Respir Crit Care Med 2014; 35: 181-200.
35. Bonella F, Volpe A, Caramaschi P, Nava C, Ferrari P, Schenk K, Ohshimo S, Costabel U, Ferrari M: Surfactant protein D and KL-6 serum levels in systemic sclerosis: correlation with lung and systemic involvement. Sarcoidosis Vasc Diffuse Lung Dis 2011; 28: 27-33.
36. Takahashi H, Kuroki Y, Tanaka H, Saito T, Kurokawa K, Chiba H, Sagawa A, Nagae H, Abe S: Serum levels of surfactant proteins A and D are useful biomarkers for interstitial lung Disease in patients with progressive systemic sclerosis. Am J Respir Crit Care Med 2000; 162: 258-263.
37. Asano Y, Ihn H, Yamane K, Yazawa N, Kubo M, Fujimoto M, Tamaki K: Clinical significance of surfactant protein D as a serum marker for evaluating pulmonary fibrosis in patients with systemic sclerosis. Arthritis Rheum 2001; 44: 1363-1369.
38. Yamane K, Ihn H, Kubo M, Yazawa N, Kikuchi K, Soma Y, Tamaki K: Serum levels of KL-6 as a useful marker for evaluating pulmonary fibrosis in patients with systemic sclerosis. J Rheumatol 2000; 27: 930-934.
39. Yanaba K, Hasegawa M, Hamaguchi Y, Fujimoto M, Takehara K, Sato S: LongituDinal analysis of serum KL-6 levels in patients with systemic sclerosis: association with the activity of pulmonary fibrosis. Clin Exp Rheumatol 2003; 21: 429-436.
40. Kinoshita F, Hamano H, Harada H, Kinoshita T, Igishi T, Hagino H, Ogawa T: Role of KL-6 in evaluating the Disease severity of rheumatoid lung Disease: comparison with HRCT. Respir Med 2004; 98: 1131-1137.
41. Nakajima H, Harigai M, Hara M, Hakoda M, Tokuda H, Sakai F, Kamatani N, Kashiwazaki S: KL-6 as a novel serum marker for interstitial pneumonia associated with collagen Diseases. J Rheumatol 2000; 27: 1164-1170.
42. De Lauretis A, Sestini P, PanteliDis P, Hoyles R, Hansell DM, Goh NS, Zappala CJ, Visca D, Maher TM, Denton CP, et al: Serum interleukin 6 is preDictive of early functional decline and mortality in interstitial lung Disease associated with systemic sclerosis. J Rheumatol 2013; 40: 435-446.
43. De Lauretis A, Renzoni EA: Molecular biomarkers in interstitial lung Diseases. Mol Diagn Ther 2014; 18: 505-522.
44. Nordenbaek C, Johansen JS, Halberg P, Wiik A, Garbarsch C, Ullman S, Price PA, Jacobsen S: High serum levels of YKL-40 in patients with systemic sclerosis are associated with pulmonary involvement. Scand J Rheumatol 2005; 34: 293-297.
45. Prasse A, Pechkovsky DV, Toews GB, Schäfer M, Eggeling S, Ludwig C, Germann M, Kollert F, Zissel G, Müller-Quernheim J: CCL18 as an inDicator of pulmonary fibrotic activity in iDiopathic interstitial pneumonias and systemic sclerosis. Arthritis Rheum 2007; 56: 1685-1693.
46. Tiev KP, Hua-Huy T, Kettaneh A, Gain M, Duong-Quy S, Toledano C, Cabane J, Dinh-Xuan AT: Serum CC chemokine ligand-18 preDicts lung Disease worsening in systemic sclerosis. Eur Respir J 2011; 38: 1355-1360.
47. Schmidt K, Martinez-Gamboa L, Meier S, Witt C, Meisel C, Hanitsch LG, Becker MO, Huscher D, Burmester GR, Riemekasten G: Bronchoalveoloar [sic!] lavage fluid cytokines and chemokines as markers and preDictors for the outcome of interstitial lung Disease in systemic sclerosis patients. Arthritis Res Ther 2009; 11:R111.
48. Andersen GN, Nilsson K, Pourazar J, Hackett TL, Kazzam E, Blomberg A, Waldenström A, Warner J, Rantapää-Dahlqvist S, Mincheva-Nilsson L, Sandström T: Bronchoalveolar matrix metalloproteinase 9 relates to restrictive lung function impairment in systemic sclerosis. Respir Med 2007; 101: 2199-2206.
49. Teirstein AS, Machac J, Almeida O, Lu P, PaDilla ML, Iannuzzi MC: Results of 188 wholebody fluorodeoxyglucose positron emission tomography scans in 137 patients with sarcoidosis. Chest 2007; 132: 1949-1953.
50. Nishiyama Y, Yamamoto Y, Fukunaga K, Takinami H, Iwado Y, Satoh K, Ohkawa M: Comparative evaluation of 18 F-FDG PET and 67 Ga scintigraphy in patients with sarcoidosis. J Nucl Med 2006; 47: 1571-1576.
51. Braun JJ, Kessler R, Constantinesco A, Imperiale A: 18 F-FDG PET/CT in sarcoidosis management: review and report of 20 cases. Eur J Nucl Med Mol Imaging 2008; 35: 1537-1543.
52. Uehara T, Takeno M, Hama M, Yoshimi R, Suda A, Ihata A, Ueda A, Tateishi U, Ishigatsubo Y: Deep-inspiration breath-hold 18 FFDG-PET/CT is useful for assessment of connective tissue Disease associated interstitial pneumonia. Mod Rheumatol 2015, Epub ahead of print.
53. Cohen C, Mekinian A, Uzunhan Y, Fauchais AL, Dhote R, Pop G, Eder V, Nunes H, Brillet PY, Valeyre D, et al: 18 F-fluorodeoxyglucose positron emission tomography/computer tomography as an objective tool for assessing Disease activity in Sjögren's syndrome. Autoimmun Rev 2013; 12: 1109-1114.
54. Briggs DC, Vaughan RW, Welsh KI, Myers A, duBois RM, Black CM: Immunogenetic preDiction of pulmonary fibrosis in systemic sclerosis. Lancet 1991; 338: 661-662.
55. Kuwana M, Kaburaki J, Mimori T, Kawakami Y, Tojo T: LongituDinal analysis of autoantibody response to topoisomerase I in systemic sclerosis. Arthritis Rheum 2000; 43: 1074-1084.
56. Hu PQ, Fertig N, Medsger TA Jr, Wright TM: Correlation of serum anti-DNA topoisomerase I antibody levels with Disease severity and activity in systemic sclerosis. Arthritis Rheum 2003; 48: 1363-1373.
57. Reveille JD, Solomon DH: Evidence-based guidelines for the use of immunologic tests: anticentromere, Scl-70, and nucleolar antiboDies. Arthritis Rheum 2003; 49: 399-412.
58. Mori S, Koga Y, Sugimoto M: Different risk factors between interstitial lung Disease and airway Disease in rheumatoid arthritis. Respir Med 2012; 106: 1591-1599.
59. Aubart F, Crestani B, Nicaise-Roland P, Tubach F, Bollet C, Dawidowicz K, Quintin E, Hayem G, Palazzo E, Meyer O, et al: High levels of anti-cyclic citrullinated peptide autoantiboDies are associated with co-occurrence of pulmonary Diseases with rheumatoid arthritis. J Rheumatol 2011; 38: 979-982.
60. Alexiou I, Germenis A, Koutroumpas A, Kontogianni A, Theodoridou K, Sakkas LI: Anti-cyclic citrullinated peptide-2 (CCP2) autoantiboDies and extra-articular manifestations in Greek patients with rheumatoid arthritis. Clin Rheumatol 2008; 27: 511-513.
61. La Corte R, Lo Mo Naco A, Locaputo A, Dolzani F, Trotta F: In patients with antisynthetase syndrome the occurrence of anti-Ro/SSA antiboDies causes a more severe interstitial lung Disease. Autoimmunity 2006; 39: 249-253.
62. Gunnarsson R, El-Hage F, Aaløkken TM, Reiseter S, Lund MB, Garen T, Molberg Ø: Associations between anti-Ro52 antiboDies and lung fibrosis in mixed connective tissue Disease. Rheumatology (Oxford) 2015, Epub ahead of print.
63. Khanna D, Gladue H, Channick R, Chung L, Distler O, Furst DE, Hachulla E, Humbert M, Langleben D, Mathai SC, et al: Recommendations for screening and detection of connective tissue Disease-associated pulmonary arterial hypertension. Arthritis Rheum 2013; 65: 3194-3201.
64. Gashouta MA, Humbert M, Hassoun PM: Update in systemic sclerosis-associated pulmonary arterial hypertension. Presse Med 2014; 43:e293-e304.
65. Hajas A, Szodoray P, Nakken B, Gaal J, Zöld E, Laczik R, Demeter N, Nagy G, Szekanecz Z, Zeher M, et al: Clinical course, prognosis, and causes of death in mixed connective tissue Disease. J Rheumatol 2013; 40: 1134-1142.
66. Wigley FM, Lima JA, Mayes M, McLain D, Chapin JL, Ward-Able C: The prevalence of unDiagnosed pulmonary arterial hypertension in subjects with connective tissue Disease at the secondary health care level of community-based rheumatologists (the UNCOVER study). Arthritis Rheum 2005; 52: 2125-2132.
67. Sanchez O, Sitbon O, Jaïs X, Simonneau G, Humbert M: Immunosuppressive therapy in connective tissue Diseases-associated pulmonary arterial hypertension. Chest 2006; 130: 182-189.
68. Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, et al: 2015 ESC/ERS Guidelines for the Diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of CarDiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European PaeDiatric and Congenital CarDiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J 2015; 46: 903-975.
69. Burke CM, Glanville AR, Morris AJ, Rubin D, Harvey JA, Theodore J, Robin ED: Pulmonary function in advanced pulmonary hypertension. Thorax 1987; 42: 131-135.
70. Nathan SD, Shlobin OA, Ahmad S, Urbanek S, Barnett SD: Pulmonary hypertension and pulmonary function testing in iDiopathic pulmonary fibrosis. Chest 2007; 131: 657-663.
71. Steen VD, Graham G, Conte C, Owens G, Medsger TA Jr: Isolated Diffusing capacity reduction in systemic sclerosis. Arthritis Rheum 1992; 35: 765-770.
72. Coghlan JG, Denton CP, Grünig E, Bonderman D, Distler O, Khanna D, Müller-Ladner U, Pope JE, Vonk MC, Doelberg M, et al: Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis 2014; 73: 1340-1349.
73. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, CorDier JF, Flaherty KR, Lasky JA, et al: An official ATS/ERS/JRS/ALAT statement: iDiopathic pulmonary fibrosis: evidence-based guidelines for Diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788-824.
74. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002; 166: 111-117.
75. Wells AU: Pulmonary function tests in connective tissue Disease. Semin Respir Crit Care Med 2007; 28: 379-388.